C12N 2760/18371
Demonstrated in vivo effect
C12N2760/18371 (Demonstrated in vivo effect) appears on 4 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 7
- Assignees
- 4
- Inventors
- 28
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 3 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant human metapneumovirus F proteins and their use14 Jul 2026US 12,679,870 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Protein-based nanoparticle vaccine for metapneumovirus1 Jul 2025US 12,343,391 B2Icosavax, Inc.
- Protein-based nanoparticle vaccine for metapneumovirus7 Nov 2023US 11,806,394 B2Icosavax, Inc.
- Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use19 Jun 2018US 9,999,663 B2Pontificia Universidad Catolica De Chile
- Protein-based nanoparticle vaccine for metapneumovirus23 Oct 2025US 2025/0325651 A1Icosavax, Inc.
- Multivalent vaccine for paramyxoviruses and uses thereof22 May 2025US 2025/0161436 A1Icosavax, Inc.
- Combination respiratory mrna vaccines9 Jan 2025US 2025/0009865 A1Sanofi
- Protein-based nanoparticle vaccine for metapneumovirus4 Jul 2024US 2024/0216499 A1Icosavax, Inc.
- Protein-based nanoparticle vaccine for metapneumovirus3 Aug 2023US 2023/0241199 A1Icosavax, Inc.
Most cited
By later US patents